

ASX ANNOUNCEMENT

BENITEC BIOPHARMA (ASX: BLT; OTC: BTEBY)

29 April 2015

BENITEC'S SENIOR VICE PRESIDENT RESEARCH & DEVELOPMENT PRESENTS AT AUSTRALIAN GENE THERAPY CONFERENCE

Sydney, Australia: Benitec Biopharma is pleased to advise that Dr David Suhy, Benitec's SVP Research & Development, will present an overview and update of Benitec's lead clinical program, TT-034, at the Australian Gene and Cell Therapy Society's 9th Biennial Conference in Melbourne today. The title of his presentation is "TT-034: A ddRNAi-based vector used for the treatment of individuals infected with the hepatitis C virus."

Benitec is pleased to be a sponsor of this meeting, which is being held at the University of Melbourne today and tomorrow. Other speakers include Benitec's collaborator at 4D Molecular Therapeutics, Professor David Schaffer, Benitec's collaborator at the University of New South Wales, Professor Maria Kavallaris, Professor Mark Kay from Stanford University, and Benitec's CEO, Dr Peter French.

Dr Suhy's presentation is attached as it contains previously un-presented data.

Ends

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

Company	Investor relations
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Kyahn Williamson Buchan Consulting Tel: 61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au

About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX:BLT; OTC:BTEBY) which has developed a patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with labs in Hayward CA (USA) and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Hepatitis C and B, drug resistant lung cancer and wet Age-related Macular Degeneration. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa.